TTLL12

Summary

TTLL12 (tubulin tyrosine ligase like 12, HGNC:28974) is a protein-coding gene on chromosome 22q13.2, encoding Tubulin–tyrosine ligase-like protein 12 (Q14166). Negatively regulates post-translational modifications of tubulin, including detyrosination of the C-terminus and polyglutamylation of glutamate residues.

Enables histone H4K20me3 reader activity and tubulin binding activity. Involved in negative regulation of type I interferon-mediated signaling pathway and regulation of mitotic cell cycle. Located in cytosol and plasma membrane.

Source: NCBI Gene 23170 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 166 total
• Druggable target: yes
• MANE Select transcript: NM_015140

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28974
Approved symbol	TTLL12
Name	tubulin tyrosine ligase like 12
Location	22q13.2
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0153
Ensembl gene	ENSG00000100304
Ensembl biotype	protein_coding
OMIM	619410
Entrez	23170

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000216129, ENST00000484118, ENST00000484711, ENST00000494035

RefSeq mRNA: 1 — MANE Select: NM_015140 NM_015140

CCDS: CCDS14047

Canonical transcript exons

ENST00000216129 — 14 exons

Exon	Start	End
ENSE00000656781	43171819	43171900
ENSE00000656788	43172403	43172554
ENSE00000656795	43173715	43173826
ENSE00000656799	43174209	43174403
ENSE00000656801	43176320	43176396
ENSE00000656803	43179619	43179752
ENSE00000656805	43179841	43180000
ENSE00000656812	43180742	43180940
ENSE00000656820	43182980	43183149
ENSE00001670000	43166622	43168159
ENSE00001925503	43186893	43187134
ENSE00003491460	43168774	43168912
ENSE00003645093	43169500	43169568
ENSE00003678619	43174499	43174615

Expression profiles

Bgee: expression breadth ubiquitous, 266 present calls, max score 97.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.5314 / max 242.9265, expressed in 1790 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
194506	20.5209	1790
194505	0.0105	7

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	97.78	gold quality
gingival epithelium	UBERON:0001949	97.15	gold quality
esophagus mucosa	UBERON:0002469	96.89	gold quality
mucosa of transverse colon	UBERON:0004991	96.56	gold quality
gingiva	UBERON:0001828	96.28	gold quality
pharyngeal mucosa	UBERON:0000355	94.66	gold quality
esophagus squamous epithelium	UBERON:0006920	94.56	gold quality
squamous epithelium	UBERON:0006914	94.42	gold quality
epithelium of esophagus	UBERON:0001976	93.93	gold quality
skin of leg	UBERON:0001511	92.07	gold quality
skin of abdomen	UBERON:0001416	91.96	gold quality
right adrenal gland	UBERON:0001233	91.79	gold quality
right adrenal gland cortex	UBERON:0035827	91.76	gold quality
vagina	UBERON:0000996	91.72	gold quality
transverse colon	UBERON:0001157	91.58	gold quality
cortical plate	UBERON:0005343	91.58	gold quality
left adrenal gland	UBERON:0001234	91.30	gold quality
left adrenal gland cortex	UBERON:0035825	91.30	gold quality
esophagus	UBERON:0001043	91.22	gold quality
oral cavity	UBERON:0000167	91.06	gold quality
tongue squamous epithelium	UBERON:0006919	90.99	gold quality
adrenal cortex	UBERON:0001235	90.92	gold quality
zone of skin	UBERON:0000014	90.75	gold quality
right ovary	UBERON:0002118	90.69	gold quality
cervix squamous epithelium	UBERON:0006922	90.65	gold quality
oviduct epithelium	UBERON:0004804	90.52	gold quality
upper leg skin	UBERON:0004262	90.25	gold quality
body of stomach	UBERON:0001161	90.17	gold quality
right frontal lobe	UBERON:0002810	90.15	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.11	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.26

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

35 targeting TTLL12, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-187-5P	99.74	70.26	1404
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-5584-3P	99.23	68.79	1351
HSA-MIR-5006-5P	98.79	66.92	1246
HSA-MIR-1301-3P	98.64	68.27	1071
HSA-MIR-5047	98.64	68.62	1035
HSA-MIR-4710	98.61	65.96	1048
HSA-MIR-3944-5P	98.50	67.55	997
HSA-MIR-138-5P	98.43	70.49	1292
HSA-MIR-7114-3P	98.42	66.53	569
HSA-MIR-4299	98.28	66.96	850
HSA-MIR-1180-5P	98.16	65.32	460
HSA-MIR-4660	97.79	67.44	1328
HSA-MIR-558	97.50	67.16	977
HSA-MIR-10398-5P	97.12	64.94	1051
HSA-MIR-1913	97.07	66.20	1417
HSA-MIR-5194	96.77	63.91	1021
HSA-MIR-4750-3P	96.65	64.38	512

Literature-anchored findings (GeneRIF, showing 5)

• Results raise the possibility that TTLL12 could contribute to tumorigenesis through effects on the cytoskeleton, tubulin modification and chromosome number stability. (PMID:20162578)
• results suggest that hTTLL12 has non-catalytic functions related to tubulin and histone modification, which could be linked to its effects on mitosis and chromosome number stability (PMID:23251473)
• A new TTLL12 isoform may be of importance for proper maintenance of lung cancer cells. (PMID:27748896)
• TTLL12 as a negative regulator of RNA-virus-induced type I IFN expression by inhibiting the interaction of VISA with other proteins. (PMID:28011935)
• TTLL12 is required for primary ciliary axoneme formation in polarized epithelial cells. (PMID:38177908)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ttll12	ENSDARG00000103537
mus_musculus	Ttll12	ENSMUSG00000016757
rattus_norvegicus	Ttll12	ENSRNOG00000022623
drosophila_melanogaster	TTLL12	FBGN0033225
caenorhabditis_elegans		WBGENE00008405

Paralogs (12): TTLL1 (ENSG00000100271), TTLL2 (ENSG00000120440), TTLL9 (ENSG00000131044), TTLL4 (ENSG00000135912), TTLL7 (ENSG00000137941), TTLL8 (ENSG00000138892), TTLL10 (ENSG00000162571), TTLL6 (ENSG00000170703), TTLL11 (ENSG00000175764), KPRP (ENSG00000203786), TTLL13 (ENSG00000213471), TTLL3 (ENSG00000214021)

Protein

Protein identifiers

Tubulin–tyrosine ligase-like protein 12 — Q14166 (reviewed: Q14166)

Alternative names: Inactive tubulin–tyrosine ligase-like protein 12

All UniProt accessions (2): Q14166, V9GY16

UniProt curated annotations — full annotation on UniProt →

Function. Negatively regulates post-translational modifications of tubulin, including detyrosination of the C-terminus and polyglutamylation of glutamate residues. Also, indirectly promotes histone H4 trimethylation at ‘Lys-20’ (H4K20me3). Probably by controlling tubulin and/or histone H4 post-translational modifications, plays a role in mitosis and in maintaining chromosome number stability. During RNA virus-mediated infection, acts as a negative regulator of the RIG-I pathway by preventing MAVS binding to TBK1 and IKBKE.

Subunit / interactions. Interacts with MAVS; the interaction prevents MAVS binding to TBK1 and IKBKE. Interacts (via N-terminus) with TBK1 (via protein kinase domain). Interacts (via TTL domain) with IKBKE (via protein kinase domain). Interacts with tubulin alpha. Interacts with histone H3 and histone H4 (when trimethylated at ‘Lys-20’ (H4K20me3)). Interacts with CBX3.

Subcellular location. Cytoplasm. Midbody. Cytoskeleton. Microtubule organizing center. Centrosome. Spindle. Nucleus.

Tissue specificity. Expressed in the basal layer of prostate and endothelial cells. Increased expression in prostatic intraepithelial neoplasia and metastatic lesions.

Similarity. Belongs to the tubulin–tyrosine ligase family.

RefSeq proteins (1): NP_055955* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004344	TTL/TTLL_fam	Family
IPR027749	TTLL12	Family
IPR057954	SET_TTL12	Domain

Pfam: PF03133, PF25556

UniProt features (13 total): sequence variant 4, binding site 3, mutagenesis site 2, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14166-F1	91.19	0.84

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 450–453; 468; 470

Mutagenesis-validated functional residues (2):

Position	Phenotype
244	decreases expression of ifnb1 mrna following infection with sendai virus.
605	decreases expression of ifnb1 mrna following infection with sendai virus.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8955332	Carboxyterminal post-translational modifications of tubulin

MSigDB gene sets: 196 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, LOPEZ_MESOTHELIOMA_SURVIVAL_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_RESPONSE_TO_PEPTIDE, MODULE_45, GOBP_RESPONSE_TO_TYPE_I_INTERFERON, GOBP_NEGATIVE_REGULATION_OF_INNATE_IMMUNE_RESPONSE, MODULE_16, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, GOBP_REGULATION_OF_CELL_CYCLE, GOCC_CENTROSOME

GO Biological Process (6): regulation of mitotic cell cycle (GO:0007346), innate immune response (GO:0045087), negative regulation of type I interferon-mediated signaling pathway (GO:0060339), immune system process (GO:0002376), chromatin organization (GO:0006325), protein modification process (GO:0036211)

GO Molecular Function (4): ATP binding (GO:0005524), histone H4K20me2 reader activity (GO:0140005), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (8): nucleus (GO:0005634), cytoplasm (GO:0005737), centrosome (GO:0005813), spindle (GO:0005819), cytosol (GO:0005829), plasma membrane (GO:0005886), midbody (GO:0030496), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
intracellular membraneless organelle	2
mitotic cell cycle	1
regulation of cell cycle	1
immune response	1
defense response to symbiont	1
negative regulation of cytokine-mediated signaling pathway	1
negative regulation of innate immune response	1
type I interferon-mediated signaling pathway	1
regulation of type I interferon-mediated signaling pathway	1
biological_process	1
cellular component organization	1
protein metabolic process	1
macromolecule modification	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
histone H4 reader activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
centriole	1
microtubule organizing center	1
microtubule cytoskeleton	1
cytoplasm	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

966 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TTLL12	TTLL4	Q14679	709
TTLL12	TTLL9	Q3SXZ7	665
TTLL12	TTLL11	Q8NHH1	664
TTLL12	TTLL1	O95922	609
TTLL12	TTL	Q8NG68	586
TTLL12	TTLL10	Q6ZVT0	547
TTLL12	TTLL5	Q6EMB2	483
TTLL12	ZNF671	Q8TAW3	457
TTLL12	NUDT14	O95848	453
TTLL12	SRPRB	Q9Y5M8	428
TTLL12	TTLL7	Q6ZT98	423
TTLL12	TTLL8	A6PVC2	391
TTLL12	TMEM53	Q6P2H8	390
TTLL12	AGTPBP1	Q9UPW5	385
TTLL12	ATAT1	Q5SQI0	371
TTLL12	LRRFIP2	Q9Y608	371

IntAct

104 interactions, top by confidence:

A	B	Type	Score
DNAJB1	TTLL12	psi-mi:“MI:0915”(physical association)	0.800
EEF1A2	TTLL12	psi-mi:“MI:0915”(physical association)	0.800
EEF1A2	EEF1B2	psi-mi:“MI:0914”(association)	0.740
EEF1A1	TTLL12	psi-mi:“MI:0915”(physical association)	0.740
DNAJB4	DNAJB5	psi-mi:“MI:0914”(association)	0.730
DNAJB1	DNAJB5	psi-mi:“MI:0914”(association)	0.640
CD27	TCAF2	psi-mi:“MI:0914”(association)	0.640
PRR35	TTLL12	psi-mi:“MI:0915”(physical association)	0.560
TTLL12	FAM222B	psi-mi:“MI:0915”(physical association)	0.560
YWHAG	SHTN1	psi-mi:“MI:0914”(association)	0.560
DNAJB4	SYNM	psi-mi:“MI:0914”(association)	0.530
EEF1A1	ZPR1	psi-mi:“MI:0914”(association)	0.530
DHX57	APOD	psi-mi:“MI:0914”(association)	0.530
EEF1AKMT1	EEF1A1	psi-mi:“MI:0914”(association)	0.530
PBDC1	EEF1A1	psi-mi:“MI:0914”(association)	0.530
EEF1A1	EEF1B2	psi-mi:“MI:0914”(association)	0.530
EEF1AKMT1	TTLL12	psi-mi:“MI:0914”(association)	0.530
DHX57	HSPA8	psi-mi:“MI:0914”(association)	0.530
Ttll12	DNAJB1	psi-mi:“MI:0915”(physical association)	0.400
CSNK2A2	TTLL12	psi-mi:“MI:0915”(physical association)	0.370
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350

BioGRID (163): TTLL12 (Affinity Capture-MS), TTLL12 (Affinity Capture-MS), TTLL12 (Affinity Capture-MS), TTLL12 (Affinity Capture-MS), TTLL12 (Proximity Label-MS), TTLL12 (Proximity Label-MS), TTLL12 (Proximity Label-MS), TTLL12 (Proximity Label-MS), TTLL12 (Proximity Label-MS), TTLL12 (Affinity Capture-MS), TTLL12 (Affinity Capture-MS), TTLL12 (Affinity Capture-MS), TTLL12 (Affinity Capture-MS), TTLL12 (Affinity Capture-MS), TTLL12 (Affinity Capture-MS)

ESM2 similar proteins: A0A1D6K6U5, A0JJZ6, A2X4M8, A2XUN8, A2YQ58, A3ACF3, A5WVX1, A7X657, A7X665, B8BDK0, F1NW29, F4JZC2, O80568, O81893, P40935, Q06AU9, Q08DF7, Q0CF71, Q0D3F2, Q0DCM5, Q0J0B2, Q0J7N5, Q10B19, Q10PI9, Q14166, Q2QMG2, Q3UDE2, Q41771, Q4WD45, Q5VQG4, Q60EJ6, Q654M1, Q69NK8, Q6ET36, Q6K7B8, Q6Z398, Q7XBW0, Q7XK25, Q84J55, Q84Y01

Diamond homologs: A4Q9E4, A4Q9E5, A4Q9F1, A6PVC2, B2GUB3, Q14166, Q1ECV4, Q23FE2, Q23TC2, Q3SZH6, Q3UDE2, Q9BWV7, Q9VM91, Q9VM92, Q9Y4R7, A2APC3, Q23K29, Q5R978, Q6EEF3, Q6EMB2, Q8CHB8, A8XXC0, Q09512, A4Q9F6, A6NNM8, P0CAZ1, P38160, P38584, P38585, Q23SI8, Q3SXZ7, Q564U4, Q641W7, Q8NG68, Q9QXJ0, A4Q9F0, A4Q9E8, A8X9V4, O95922, P0CAZ0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

166 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	127
Likely benign	17
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

2507 predictions. Top by Δscore:

Variant	Effect	Δscore
22:43168768:TCTTA:T	donor_loss	1.0000
22:43168769:CTTA:C	donor_loss	1.0000
22:43168770:TTA:T	donor_loss	1.0000
22:43168771:TAC:T	donor_loss	1.0000
22:43168772:A:AC	donor_gain	1.0000
22:43168772:A:C	donor_loss	1.0000
22:43168773:C:CC	donor_gain	1.0000
22:43168773:C:CG	donor_loss	1.0000
22:43168773:CCAT:C	donor_gain	1.0000
22:43168909:CAGC:C	acceptor_gain	1.0000
22:43168912:CCT:C	acceptor_loss	1.0000
22:43168913:C:CC	acceptor_gain	1.0000
22:43168914:T:A	acceptor_loss	1.0000
22:43169496:TTA:T	donor_loss	1.0000
22:43169497:TA:T	donor_loss	1.0000
22:43169498:A:AC	donor_gain	1.0000
22:43169498:A:C	donor_loss	1.0000
22:43169499:C:CC	donor_gain	1.0000
22:43169499:C:CT	donor_loss	1.0000
22:43169564:TGCAC:T	acceptor_gain	1.0000
22:43169566:CAC:C	acceptor_gain	1.0000
22:43169567:AC:A	acceptor_gain	1.0000
22:43169568:CC:C	acceptor_gain	1.0000
22:43169569:C:CC	acceptor_gain	1.0000
22:43169569:CTGCA:C	acceptor_loss	1.0000
22:43169570:T:G	acceptor_loss	1.0000
22:43171813:CCCTA:C	donor_loss	1.0000
22:43171814:CCTAC:C	donor_loss	1.0000
22:43171815:CTA:C	donor_loss	1.0000
22:43171816:TACC:T	donor_loss	1.0000

AlphaMissense

4254 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:43173799:C:A	K419N	0.998
22:43173799:C:G	K419N	0.998
22:43168122:G:C	N607K	0.997
22:43168122:G:T	N607K	0.997
22:43168806:T:A	D584V	0.996
22:43168806:T:G	D584A	0.996
22:43168816:A:C	Y581D	0.996
22:43174334:C:A	K368N	0.996
22:43174334:C:G	K368N	0.996
22:43168805:G:C	D584E	0.995
22:43168805:G:T	D584E	0.995
22:43173801:T:C	K419E	0.995
22:43174565:A:G	F323S	0.995
22:43168119:G:C	F608L	0.994
22:43168119:G:T	F608L	0.994
22:43168121:A:G	F608L	0.994
22:43168803:A:G	L585P	0.994
22:43168812:G:T	A582D	0.994
22:43168822:C:G	A579P	0.994
22:43169514:A:G	W544R	0.994
22:43169514:A:T	W544R	0.994
22:43173810:A:G	W416R	0.994
22:43173810:A:T	W416R	0.994
22:43180918:A:G	W124R	0.994
22:43180918:A:T	W124R	0.994
22:43168114:G:T	P610H	0.993
22:43168129:T:A	E605V	0.993
22:43168806:T:C	D584G	0.993
22:43168807:C:G	D584H	0.993
22:43171846:G:C	N516K	0.993

dbSNP variants (sampled 300 via entrez): RS1000009589 (22:43170537 T>G), RS1000120986 (22:43170042 C>T), RS1000148118 (22:43175825 A>C), RS1000268178 (22:43184065 G>A), RS1000313251 (22:43166622 T>C), RS1000441759 (22:43172502 C>T), RS1000594006 (22:43176539 G>A), RS1000724992 (22:43180687 G>A,C,T), RS1000741086 (22:43186905 C>G,T), RS1000793608 (22:43187072 C>T), RS1000834103 (22:43184987 C>A,G), RS1001102176 (22:43167529 T>G), RS1001175425 (22:43175835 A>C,G), RS1001252571 (22:43174904 G>A,T), RS1001314667 (22:43178372 A>G)

Disease associations

OMIM: gene MIM:619410 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002114_5	Molar-incisor hypomineralization	4.000000e-07
GCST004625_197	Monocyte count	4.000000e-22
GCST90002393_593	Monocyte count	6.000000e-43
GCST90002400_513	Plateletcrit	1.000000e-14
GCST90002402_652	Platelet count	2.000000e-12

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0005321	molar-incisor hypomineralization
EFO:0005091	monocyte count
EFO:0007985	platelet crit
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066513 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.10	Kd	7967	nM	CHEMBL5653589
5.10	ED50	7967	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149672: Binding affinity to human TTLL12 incubated for 45 mins by Kinobead based pull down assay	kd	7.9669	uM

CTD chemical–gene interactions

60 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects binding, increases reaction, decreases expression, affects cotreatment, increases abundance (+1 more)	5
Valproic Acid	affects expression, increases expression, increases methylation	3
bisphenol A	decreases expression, increases expression	2
cobaltous chloride	decreases expression	2
Air Pollutants	increases abundance, increases expression, decreases expression	2
Arsenic	increases abundance, increases expression, affects methylation, affects cotreatment	2
Smoke	increases abundance, increases expression, decreases expression	2
Tretinoin	decreases expression	2
Cadmium Chloride	decreases expression, increases expression	2
Particulate Matter	increases abundance, affects cotreatment, increases expression, decreases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
dicrotophos	increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression, increases expression	1
decabromobiphenyl ether	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
tetrabromobisphenol A	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	increases expression	1
LDN 193189	affects cotreatment, decreases expression	1
NSC 689534	affects binding, decreases expression	1
Temozolomide	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652714	Binding	Binding affinity to human TTLL12 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3K9	Abcam HEK293T TTLL12 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.